ClinicalTrials.gg
RecruitingNCT07493317Updated Apr 29, 2026

Neutralizing Interleukin (IL)-6

A Phase 2 interventional study of Tocilizumab in Major Depressive Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Major · Icahn School of Medicine at Mount Sinai.

Planned enrollment
6th of 18
60 · median 34
Started
2026
with 1 other
Phase 2
8 of 19
4 open now
Registered
18th of 19
by date

Among the 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 in phase 2, and was the 18th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

4 of the 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major Depressive Disorder (MDD) and evidence of peripheral immune activation. IL-6 is a pro-inflammatory cytokine implicated in the pathophysiology of depression. The investigators hypothesize that neutralizing peripheral immune signaling via IL-6 receptor blockade with tocilizumab will improve neural and behavioral measures of reward processing. This is an open-label, proof-of concept, trial in which up to N=20 adults with MDD meeting a specific immune enrichment criterion will receive open-label tocilizumab over 8 weeks. A healthy control (HC) group (N=20) will undergo baseline neuroimaging and blood-based biomarker assessment without receiving the study drug to aid interpretation of findings. Blood-based immune markers and brain MRI scans (including task-based reward activation and resting-state functional connectivity) will be assessed at baseline for all participants and again post treatment for the MDD group.

Read the detailed description

This open-label, proof-of-concept interventional study is designed to evaluate the feasibility and safety of IL-6 receptor blockade using subcutaneous tocilizumab in adults with MDD and evidence of peripheral immune activation.

Participants with MDD (N=20) meeting immune enrichment criteria (elevated monocyte count) will receive tocilizumab 162 mg administered subcutaneously every 2 weeks for 8 weeks (5 total doses).

A comparison group of healthy volunteers (N=20) will undergo baseline neuroimaging and blood sampling but will not receive study drug.

The primary objective is to assess change in neural reward circuitry function, measured by ventral striatal activation during reward processing tasks using functional MRI.

Secondary objectives include evaluating changes in anhedonia and depressive symptoms using validated clinical scales (SHAPS, MADRS, TEPS), as well as changes in peripheral immune biomarkers.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Monoclonal antibody
  • Healthy Volunteer
  • Tocilizumab
  • Interleukin-6
  • Anhedonia
  • fMRI
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For MDD participants:

  • Written ;
  • Ability to comply with the requirements of the study as determined by the PI;
  • Ages 18-70 years;
  • Any gender;
  • diagnosis of MDD in a current Major Depressive Episode;
  • Immune enrichment criterion: elevated monocyte count ≥ 500 cells/μL at screening;
  • If patient is on antidepressant medication, they must be on a stable dose for ≥4 weeks prior to treatment;
  • SHAPS score ≥20
  • If female of , must agree to use of a medically accepted form of , or else agree to abstinence until 6 months after the last dose of study drug;
  • Male patients, if heterosexually active with a partner who is female of childbearing potential, pregnant, or breastfeeding, must agree to barrier contraception for the treatment period and for at least 6 months after the last dose of the study drug. Female partners of male participants must use at least one form of highly effective contraception starting at least one cycle prior to male patient study drug initiation until 6 months after the last dose of study drug.
  • Meet all MRI safety criteria.

For Healthy Volunteers:

  • Written informed consent;
  • Ability to comply with the requirements of the study as determined by the PI;
  • Ages 18-70
  • Any gender;
  • No current or past DSM-5 psychiatric disorder;
  • Meet all MRI safety criteria.

Exclusion criteria

Exclusion Criteria:

For MDD Participants

  • A primary psychiatric diagnosis other than MDD, with the exception of comorbid anxiety disorders (including agoraphobia, generalized anxiety disorder, social anxiety disorder, panic disorder) and post-traumatic stress disorder, which are permitted.
  • History of schizophrenia, schizoaffective disorder, other psychotic disorder, MDD with psychotic features, or bipolar I or II disorder.
  • Diagnosis of a major neurocognitive disorder.
  • Moderate or severe substance use disorder within the past 6 months (excluding nicotine use disorder).
  • Positive urine toxicology screen for illicit substances at screening.
  • Serious or imminent risk of self-harm or violence, as determined by the PI, including:

    • Suicide attempt within the past 2 years, or
    • C-SSRS ideation score >2 within the past month.
  • Any to MRI, including claustrophobia, retained metallic foreign bodies, magnetic implants or pacemakers, or inability to tolerate MRI procedures.
  • abnormalities on physical examination or laboratory testing.
  • Unstable or clinically significant medical illness, including but not limited to hepatic, renal, gastrointestinal, respiratory, cardiovascular (including ischemic heart disease), endocrine, neurologic (including history of severe head injury), immunologic, or hematologic conditions.
  • Evidence of active or untreated infection, including
  • Active tuberculosis (TB) or untreated latent TB
  • Positive QuantiFERON-TB Gold test at screening
  • Known infection
  • Active or infection
  • Current or recent (within an appropriate ) use of biologic therapies or other agents (PRN NSAIDs permitted).
  • Known to tocilizumab or its .
  • Receipt of a live or within 30 days prior to first dose, or planned receipt during the study period.
  • Pregnancy, breastfeeding, or unwillingness to use effective during the study and for 6 months after the last dose.
  • Any condition that, in the opinion of the PI, would compromise participant safety or data integrity.

For Healthy Volunteers

  • Any current or unstable medical illness, including hepatic, renal, gastrointestinal, respiratory, cardiovascular (including ischemic heart disease), endocrine, neurologic (including history of severe head injury), immunologic, or hematologic disease.
  • Use of biologic therapies or immunosuppressive agents (PRN NSAIDs permitted).
  • Positive urine toxicology screen for illicit substances at screening.
  • Pregnancy at the time of baseline assessments (e.g., MRI).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Participants with MDD

    MDD participants will receive 5 doses of tocilizumab 162 mg administered via subcutaneous injection every 2 weeks over an 8-week period.

    Drug: Tocilizumab

  • No intervention
    Healthy Control

    Healthy controls will serve as a baseline comparison group for neuroimaging and biomarker analyses only.

Interventions

  • One treatment condition in an open-label study design: subcutaneous injection of tocilizumab 162 mg at weeks 0, 2, 4, 6, and 8.

06

What researchers measure

Primary outcomes

  1. Change in ventral stratal activation during reward processing (fMRI)

    Change in ventral stratal activation (brain response) during reward processing (fMRI)

    Time frame: at week 0 and week 10

Secondary outcomes

  1. Change in Snaith-Hamilton Pleasure Scale (SHAPS)

    Changes in the following scales from baseline to end of treatment: Snaith-Hamilton Pleasure Scale (SHAPS): SHAPS total score ranges from 14 to 56, with higher scores indicating greater anhedonia.

    Time frame: at week 0 and week 12

  2. Change in Montgomery-Asberg Depression Rating Scale (MADRS)

    Changes in the following scales from baseline to end of treatment: Montgomery-Asberg Depression Rating Scale (MADRS): MADRS total score ranges from 0 to 60, with higher scores indicating greater depression severity.

    Time frame: at week 0 and week 12

  3. Change in Temporal Experience of Pleasure Scale (TEPS)

    Changes in the following scales from baseline to end of treatment: Temporal Experience of Pleasure Scale (TEPS): TEPS total score ranges from 25 to 120, with lower scores indicating greater anhedonia severity.

    Time frame: at week 0 and week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to privacy concerns related to sensitive psychiatric and neuroimaging data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2031, 58 months after the start.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 58 months is above that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 25, 2026
StartActual
Mar 26, 2026
Primary completionEst.
Feb 6, 2031
CompletionEst.
Feb 6, 2031
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07493317
Responsible party
James Murrough (Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Mar 25, 2026
Start date
Mar 26, 2026
Primary completion
Feb 6, 2031 (estimated)
Completion
Feb 6, 2031 (estimated)
Last update
Apr 29, 2026

Study contacts

Alexia Lizzano
Contact
alexia.lizzano@mssm.edu
3322437059
Mackenzie Hargrove
Contact
mackenzie.brown@mssm.edu
3322437052
James Murrough
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion